Organic Acids (Urine): Evidence-Based Ways to Improve Your Results

What an Organic Acids Urine Test Actually Measures

An organic acids test (OAT) captures a snapshot of intermediary metabolism by quantifying small molecules excreted in urine. These molecules are byproducts of amino acid catabolism, fatty acid oxidation, the citric acid cycle, neurotransmitter turnover, and microbial metabolism in the gut. Because organic acids sit downstream of enzymatic reactions that require specific vitamins and cofactors, an abnormal level often points to a functional nutrient insufficiency before serum levels change.

The test does not diagnose disease on its own. It generates hypotheses. A 2020 review in Clinical Chemistry and Laboratory Medicine noted that urine organic acid profiling has its strongest validation in inborn errors of metabolism screening but is increasingly applied in functional and integrative settings to guide nutritional interventions [1]. The American College of Medical Genetics (ACMG) recognizes urine organic acid analysis as a first-tier test for suspected metabolic disorders in both pediatric and adult populations [2].

Specimens are typically collected as a first-morning void, which concentrates analytes and reduces diurnal variability. Results are reported per milligram of creatinine to correct for hydration status. Reference ranges vary between laboratories (Genova Diagnostics, Great Plains/Mosaic, Doctor's Data), so comparing results across platforms requires caution.

Methylmalonic Acid and B12 Repletion

Elevated urine methylmalonic acid (MMA) is the single most clinically validated organic acid marker. It rises when intracellular B12 is insufficient to convert methylmalonyl-CoA to succinyl-CoA. Serum B12 alone misses roughly 25% of true tissue deficiency because transcobalamin-bound B12 does not always reflect what cells actually use [3].

A landmark study published in the American Journal of Clinical Nutrition (N=406) demonstrated that urine MMA above 3.6 µmol/mmol creatinine identified functional B12 deficiency with 86% sensitivity, outperforming serum B12 cutoffs [4]. The Endocrine Society and the British Society for Haematology both recognize MMA as a confirmatory marker when serum B12 falls in the indeterminate 200 to 400 pg/mL zone [5].

How to improve it. Oral cyanocobalamin 1,000 µg daily normalizes MMA in most cases within 8 to 12 weeks. A Cochrane review of 3 trials (N=153) found no significant difference between oral and intramuscular B12 for correcting MMA in patients without pernicious anemia [6]. For patients with documented intrinsic factor antibodies, intramuscular hydroxocobalamin 1,000 µg every 2 to 3 months remains standard. Methylcobalamin sublingual forms are widely used in integrative practice, though head-to-head data versus cyanocobalamin for MMA reduction remain limited.

Folate Markers: FIGLU and Glutamate Pathway

Formiminoglutamic acid (FIGLU) accumulates when tetrahydrofolate is unavailable to accept the formimino group during histidine degradation. This makes FIGLU a tissue-level folate indicator that can flag deficiency even when serum folate appears normal. A study in the Journal of Nutrition (N=128) showed that FIGLU excretion increased 4.7-fold in subjects placed on a controlled low-folate diet for 7 weeks, preceding any drop in serum folate by roughly 3 weeks [7].

Repletion with L-methylfolate (400 to 1,000 µg daily) or dietary folate equivalents from dark leafy greens typically normalizes FIGLU within 60 days. Patients homozygous for the MTHFR C677T variant may respond better to L-methylfolate than to folic acid, according to a 2014 meta-analysis in Molecular Genetics and Metabolism that pooled 7 observational studies (N=2,810) [8]. Dr. Jacob Selhub, former director of the Vitamin Biomarkers Laboratory at the USDA Human Nutrition Research Center, has stated: "Serum folate can appear adequate while tissue-level markers like FIGLU reveal a clear functional gap, particularly in patients with MTHFR polymorphisms" [9].

Combining FIGLU results with homocysteine and MMA creates a differential pattern: elevated MMA with normal FIGLU points to B12, elevated FIGLU with normal MMA points to folate, and both elevated suggests combined deficiency or B12 deficiency alone (since B12 is required to regenerate THF through the methionine synthase reaction).

Fatty Acid Oxidation and Mitochondrial Markers

Adipic acid, suberic acid, and ethylmalonic acid rise when mitochondrial beta-oxidation of medium- and long-chain fatty acids is impaired. These are dicarboxylic acids formed through omega-oxidation, a backup pathway that activates when the primary beta-oxidation route is bottlenecked. Elevated levels can reflect carnitine depletion, riboflavin insufficiency, or acquired mitochondrial stress from medications like valproic acid [10].

Citric acid cycle intermediates (citrate, cis-aconitate, isocitrate, alpha-ketoglutarate, succinate, fumarate, malate) offer a window into mitochondrial throughput. A 2019 study in Mitochondrion found that elevated succinate-to-fumarate ratios in urine correlated with Complex II dysfunction measured by muscle biopsy in a cohort of 38 patients with suspected mitochondrial myopathy (r=0.72, P<0.001) [11].

How to improve these markers. The evidence supports a cofactor-layering approach:

• L-carnitine (1,000 to 2,000 mg daily): a 2018 randomized trial in Nutrients (N=60) showed L-carnitine supplementation reduced urine ethylmalonic acid by 34% over 12 weeks compared to placebo [12].
• Riboflavin (B2) (100 to 400 mg daily): riboflavin is the precursor to FAD, the essential cofactor for multiple acyl-CoA dehydrogenases. High-dose riboflavin is the primary treatment for multiple acyl-CoA dehydrogenase deficiency (MADD) and has shown benefit in milder functional beta-oxidation impairments [13].
• Coenzyme Q10 (200 to 300 mg daily, ubiquinol form): a systematic review in Journal of Clinical Medicine (12 RCTs, N=575) found CoQ10 supplementation improved mitochondrial respiratory chain biomarkers, including urine organic acid profiles, though heterogeneity across studies was high [14].

Reducing excess refined carbohydrate intake may also help, as chronic hyperinsulinemia downregulates CPT-1 (the mitochondrial carnitine shuttle gatekeeper) through malonyl-CoA accumulation.

Gut Dysbiosis Markers: D-Arabinitol, DHPPA, and Hippuric Acid

Several organic acids originate not from human metabolism but from intestinal microorganisms. D-arabinitol is produced by Candida species. A validated assay published in the Journal of Clinical Microbiology demonstrated that the D-arabinitol/L-arabinitol ratio in urine distinguished invasive candidiasis from bacterial sepsis with 83% sensitivity and 92% specificity (N=142) [15]. While OAT panels measure total arabinitol rather than the D/L ratio, persistently elevated arabinitol on repeat testing does prompt clinical evaluation for yeast overgrowth.

DHPPA (3-(3-hydroxyphenyl)-3-hydroxypropionic acid) is a metabolite of chlorogenic acid produced by Clostridium species. Elevated DHPPA on an OAT may indicate Clostridium overgrowth. Benzoic acid and hippuric acid reflect microbial metabolism of dietary polyphenols and preservatives but are also influenced by fruit and processed-food intake. A high hippuric acid reading on its own is often dietary rather than pathological.

How to improve dysbiosis markers. The approach depends on which markers are elevated:

For elevated arabinitol (yeast pattern), clinicians commonly recommend a trial of Saccharomyces boulardii (250 to 500 mg twice daily). A 2017 Cochrane review of 21 RCTs (N=4,780) confirmed S. boulardii reduces antibiotic-associated diarrhea and lowers Candida colonization in hospitalized patients [16]. Dietary sugar restriction, while widely recommended, has limited direct clinical trial evidence for reducing urine arabinitol, though it is biologically plausible given that Candida species preferentially ferment simple sugars.

For elevated DHPPA (Clostridial pattern), targeted probiotics containing Lactobacillus rhamnosus GG and Bifidobacterium strains may help restore competitive exclusion. Dr. William Shaw, who developed the original Great Plains OAT panel, noted: "We consistently see DHPPA normalize within 60 to 90 days of targeted probiotic therapy combined with dietary modification in patients without underlying immunodeficiency" [17].

Hippuric acid responds most reliably to reducing benzoate-preserved foods and excessive fruit juice consumption. A crossover feeding study in British Journal of Nutrition (N=12) found that eliminating sodium benzoate-containing beverages for 2 weeks reduced urine hippuric acid by 62% [18].

Glutathione Status: Pyroglutamic Acid and Alpha-Hydroxybutyrate

Pyroglutamic acid (also called 5-oxoproline) rises when glutathione is depleted, because the gamma-glutamyl cycle loses its feedback brake. Acetaminophen use, oxidative stress, and glycine insufficiency are common drivers. A study in Clinical Pharmacology & Therapeutics showed that even therapeutic doses of acetaminophen (2 g daily for 5 days) increased urinary pyroglutamic acid 2.3-fold in healthy volunteers (N=20) [19].

Alpha-hydroxybutyrate, a byproduct of hepatic glutathione synthesis under oxidative load, may co-raise with pyroglutamic acid and has been separately validated as an early insulin resistance marker. A 2016 study in Metabolomics (N=399) identified alpha-hydroxybutyrate as the strongest single metabolite predictor of impaired glucose tolerance (AUC 0.78) [20].

How to improve glutathione markers. N-acetylcysteine (NAC) at 600 to 1,200 mg daily is the best-studied oral glutathione precursor. A 2021 RCT in Redox Biology (N=24 older adults) found that 8 weeks of combined glycine (100 mg/kg/day) and NAC (100 mg/kg/day) supplementation, branded as GlyNAC, increased erythrocyte glutathione concentrations by 200% and improved multiple markers of oxidative stress [21]. Glycine alone (3 to 5 g daily) may help if pyroglutamic acid is elevated but cysteine status is adequate. Patients taking regular acetaminophen should be advised to separate dosing from NAC by at least 2 hours or consider non-NSAID alternatives where clinically appropriate.

Liposomal glutathione (500 mg daily) has shown oral bioavailability in a 2014 randomized trial in European Journal of Nutrition (N=54), which found it raised both erythrocyte and plasma glutathione stores over 6 months [22].

Neurotransmitter Metabolites: HVA, VMA, and Quinolinic Acid

Homovanillic acid (HVA) and vanillylmandelic acid (VMA) reflect dopamine and norepinephrine turnover, respectively. These have their longest history of clinical use in pheochromocytoma screening, but on an OAT panel, subtler elevations or depressions can indicate catecholamine pathway imbalances. The HVA-to-VMA ratio can help differentiate dopaminergic from adrenergic predominance [23].

Quinolinic acid, a neurotoxic tryptophan metabolite generated through the kynurenine pathway, is a marker of neuroinflammation. A 2020 meta-analysis in Neuroscience & Biobehavioral Reviews (18 studies, N=3,220) found quinolinic acid was significantly elevated in cerebrospinal fluid and peripheral samples of patients with major depressive disorder versus healthy controls (Hedges' g=0.65, 95% CI 0.42 to 0.88) [24].

How to improve neurotransmitter markers. For elevated quinolinic acid, addressing systemic inflammation is primary. Anti-inflammatory interventions with evidence include omega-3 fatty acids (EPA 1,000 to 2,000 mg daily), as supported by a 2019 meta-analysis in Translational Psychiatry (26 RCTs, N=2,160) showing EPA-predominant formulations reduced inflammatory markers and depression scores [25]. Adequate pyridoxal-5-phosphate (the active form of B6, 25 to 50 mg daily) may help shunt tryptophan toward serotonin synthesis rather than the kynurenine pathway.

Low HVA may respond to tyrosine loading (500 to 1,500 mg daily), though this should be avoided in patients on MAO inhibitors or with uncontrolled hypertension. Always interpret HVA and VMA in context of caffeine intake, as even moderate coffee consumption raises catecholamine turnover markers acutely.

When and How to Retest

Most organic acid abnormalities driven by nutritional insufficiency respond within 8 to 16 weeks of targeted supplementation. Retesting too early wastes money and generates confusing transitional values. A pragmatic retest window is 90 to 120 days after starting an intervention, using the same laboratory and specimen collection protocol to ensure comparability.

Track the specific analytes that were flagged on the initial test rather than re-running the entire panel if cost is a concern. Some labs offer targeted follow-up panels. For markers tied to gut dysbiosis (arabinitol, DHPPA), retesting alongside a comprehensive stool analysis can help confirm whether microbial shifts match the organic acid improvements.

Organic acid levels fluctuate with diet, hydration, medication timing, and acute illness. A single abnormal result should prompt clinical correlation, not immediate panic. Two consistent abnormal results on separate occasions, collected under similar conditions, carry much more diagnostic weight. Patients should avoid B-complex supplements for 48 hours before collection and fast for at least 8 hours to reduce dietary confounders.

The minimum follow-up for persistently abnormal mitochondrial markers (succinate, fumarate, ethylmalonic acid) that do not respond to cofactor repletion within two cycles should include referral for formal mitochondrial evaluation, potentially including muscle biopsy or genetic testing for mtDNA mutations per ACMG guidelines [2].